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For years, the promise of psychedelics in therapeutic settings has been deterred by their 
general illegality. However, present day research shows promise in treating varying mental 
disorders. Amongst these disorders is Post Traumatic Stress Disorder (PTSD). According to 
the organization, PTSD United, PTSD presently effects about eight percent of Americans. 
Many of the current treatments only offer symptomatic relief and do not work for every 
case of PTSD. Psychedelics presently offer an alternative method of healing that focuses on 
treatment of the core issue with an emphasis on human connection and guided 
confrontation of emotions and/or trauma. Currently, it is one of the few PTSD-based 
therapies that allows for physical contact in the form of comfort and solidarity in the human 
connection. Presently, there is a need to further research into how psychedelic drugs can 
help those struggling with PTSD.
MDMA is relatively low-risk in its pure state, especially at lower doses. (Parrott, 2013). MDMA reduces brain activity in the amygdala, 
the area of the brain responsible for fear responses, suggesting that it may make revisitation of traumatic memories easier. (Thal & 
Lommen, 2018). Studies addressing concerns of MDMA’s effects on long-term cognitive ability have found no difference between 
moderate-use participants’ and nondrug participants’ cognitive abilities. However, heavy-use participants exhibited a decrease in cognitive 
abilities. (Garcia-Romeu & Kersgaard, 2016)
Doses between 50 and 75 mg were found to be both physically and psychologically safe for participants. (Bouso, Doblin, & al., 2008). 
MDMA affects the left portion amygdala, allowing for participants to feel less anxious and fearful and allow them the ability to revisit 
traumatic memories and experiences without feeling previously mentioned emotions. (Bouso, Doblin, & al., 2008). A study done by 
Bouso, Doblin, & al., using the Severity of Symptoms Scale for PTSD (SSSPTSD) which can be broken to assess symptoms of re-
experiencing trauma, increased arousal in fear, avoidance, and somatic symptoms of anxiety, showed that a total mean of 41.5 out of 51 
overall on the scale with a score of 12.7 out of 15 relating to re-experiences, 11.7 out of 15 relating to increased arousal, 16.2 out of 21 
relating to avoidance, and 24.5 out of 39 relating to somatic symptoms of anxiety. Post results of participants in the MDMA group scored 
a mean of 28.3 out of 51 overall, 10 out of 15 relating to re-experiences, 6.6 out of 15 relating to increased arousal in fear, 11.6 out of 21 
relating to avoidance, and 20 out of 39 relating to somatic symptoms of arousal. “....an overall remission rate of 66.2% and low rates of 
adverse effects have been found in the six phase two trials conducted in clinical setting with 105 blinded subjects with chronic PTSD.” 
(Thal & Lommen, 2018)
Positive and negative traits can be attributed to personal mindset and overall setting before and after administration. (Tyls, Palenicek, & 
Horacek, 2014)The toxicity for psilocybin is low; the dosage require for an overdose is much higher than the psychoactive dosage 
typically taken. (Tyls, Palenicek, & Horacek, 2014).
Psilocybin affects the hippocampus, temporarily suppressing the brain’s fear response. (Catlow, Song, Paredes, Kirstein, & Sanchez-
Ramos, 2013) Psilocybin reduces activity in the amygdala, associated with communicating fear and threat signals to the frontal cortex, in 
return shifting from negative to positive valence. (Kraehenmann, Schmidt, & al., 2016). Psilocybin has also shown to allow for more 
vivid memories. (Cahart-Harris, Leech, & al., 2012). Study comparing psilocybin and a placebo had a p-value of .004
Hypothesis
Will there be significant differences regarding the effects of MDMA and Psilocybin in the treatment of 
PTSD? If so, which of these drugs will be the most beneficial?
Both MDMA and psilocybin affect areas of the brain associated with fear response. Therefore, the usage of 
these drugs should help alleviate stress and anxiety as well as any corresponding symptoms associated with 
the re-visitation of painful memories, making it easier for participants to work through these memories with 
trained therapists than participants who are given a dose of placebo.
We predict that, consistent with prior research, that there will be a significant difference (p<0.001) between 
the placebo group and MDMA and psilocybin groups in terms of continuing improvement in scores and 
remission rates.
Participants who are given MDMA should show higher improvement relating to PTSD symptoms than 
those given psilocybin. However, those given psilocybin should still show higher improvement than those 
given a placebo.
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• Participants will include Veterans diagnosed with Post-Traumatic Stress Disorder (PTSD)
• Predicted Sample Size: 16
• Qualifications for Study:
Participants must have served in the military.
Participants must have score of 3 or higher on the CAPS scale.
Participants must not be undergoing any other forms of psychotherapy or drug 
therapy while undergoing treatment in study.




• Trained guides and therapists, one of each per participant, present during all sessions.
• Exposure-based psychotherapy aided by either MDMA, psilocybin, or placebo.
• Three government-approved PTSD scale tests given before sessions and after periodically.
• Safe and effect dosages given during session
MDMA: between 75-125 mg
Psilocybin: between 0.045 to 0.429 mg
• Follow-up therapy sessions conducted after dose session
Measurements to be administered before and after treatment as well as during follow-up sessions. 
Measurements are official measures taken from U.S. Department of Veteran Affairs
Clinical-Administered PTSD Scale (CAPS)
Scale of 0-4 used to access level of severity of trauma
Dissociative Subtype of PTSD Scale (DSPS)
Includes three sub-scales focusing on PTSD symptoms of depersonalization, 
lack of awareness, and psychogenic amnesia
Measures frequency on scale of 1-4 and severity on scale of 1-5
Difficulty Living and Working Environmental Scale (DDRI-2, Sec. C)
Score range from 14-70
Analytical Plan
In order to analyze the individual results of each group and their relations to 
the three different scales, we will conduct a one-way ANOVA.
If the hypotheses are confirmed, this would add support to the already growing range of alternative treatment 
options involving psychedelics for patients suffering from PTSD. Furthermore, this treatment path would less 
suppress symptoms, typical of most drugs used in the treatment of PTSD, and more help patients, in a safe setting 
with a trained therapist, work through traumatic memories and the emotions associated with those memories. This in 
return should allow patients with PTSD to have lowered scores on the CAPS, DSPS, and DDRI-2, Sec. C and 
therefore a better quality of life. Overall, confirmed hypotheses should correlate with a breakthrough in the overall 
treatment of PTSD.
Possible limitations may include:
• A need for more research to be fully conducted before results are accepted
• A limited sample size
• Treatment may vary based on individual cases and may not work for all persons suffering from PTSD
• There are legal implications that could slow further research
Guidelines are taken  from the Multidisciplinary Association  for Psychedelics Studies (MAPS) provided guide for the use of MDMA in treatment of 
PTSD.
Guidelines for Treatment Sessions
Preparatory:
Trained professionals and 
patient are mindful of the 
role they are playing and 
fully prepared to undergo 
treatment session.
Setting properly prepared for 
any possible needs of the 
patient.
Dosage administered; short 
session incorporated before 
effects take place.
During:
Therapists are mindful of 
their role as guides, listeners, 
and caretakers for their 
patients, maintaining a safe 
space and reassurance.
Engage in breathing exercises 
at the beginning of the onset 
of the substance. Interaction 
periods here should be 
evenly engagement and self-
exploratory.
During the peak effect, the 
patient should be fully 
engaged in self-exploration 
and any trauma; typically 




As effects wear, therapy 
session may be conducted if 
patient so wishes. This 
session incorporates any 
outside sources, such as a 
significant other.
Any more substance-induced 
sessions should be 
conducted a few weeks after.
Weekly therapy sessions 
should be conducted as well 
as monthly physical check-
ups on-site. Post scores will 






Figure A: Brain Scan: PTSD Brain vs. Non-PTSD Brain
Figure B: Brain Scan MDMA
Figure C: Brain Scan: Psilocybin
PTSD specifically affects the HPA axis, areas 
of the limbic system (amygdala, hippocampus, 
anterior cingulate), medial prefrontal cortex, 
anterior cingulate, and the frontal lobe
MDMA specifically affects areas of the limbic 
system (the left portion of the amygdala, basal 
ganglia, hypothalamus, hippocampus) and the 
neocortex
Psilocybin specifically affects the limbic 
system (hippocampus, amygdala, thalmus) and 
the frontal/posterior cingulate/medial 
prefrontal/occipital cortexes
